Alopecia Areata Update

Dermatologic Clinics

Volumn 31, Issue 1, 2013, Pages 93-108

  Alkhalifah, Abdullah ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

Alopecia areata; Autoimmune; Contact immunotherapy; Corticosteroids; Intralesional; Phototherapy; Totalis; Universalis

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; AZATHIOPRINE; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BEXAROTENE; BIMATOPROST; CAPSAICIN; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DESOXIMETASONE; DEXAMETHASONE; DIPHENCYPRONE; DITHRANOL; IMMUNOLOGIC AGENT; LATANOPROST; LATTISSE; METHOTREXATE; METHYLPREDNISOLONE; MINOXIDIL; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTAGLANDIN DERIVATIVE; SALAZOSULFAPYRIDINE; SQUARIC ACID DIBUTYL ESTER; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ACNE; AGE; ALOPECIA AREATA; AMINOTRANSFERASE BLOOD LEVEL; ATROPHY; AUTOIMMUNE DISEASE; BLISTER; BLOOD ANALYSIS; BURNING SENSATION; CATARACT; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; CONTACT DERMATITIS; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DYSMENORRHEA; ERYTHEMA MULTIFORME; EYE IRRITATION; FACE EDEMA; FLU LIKE SYNDROME; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPEREMIA; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPOPIGMENTATION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOCYTOPENIA; MOOD DISORDER; NAUSEA; NEPHROTOXICITY; OBESITY; OCCIPITAL LYMPHADENOPATHY; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; REVIEW; SCALP; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; SOCIAL SUPPORT; TELANGIECTASIA; TREATMENT FAILURE; TREATMENT PLANNING; VESICULAR RASH; VITILIGO;

AGE FACTORS; ALOPECIA AREATA; HAIR; HAIR FOLLICLE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84869169222     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.08.010     Document Type: Review

References (174)

1. Alkhalifah A., Alsantali A., Wang E., et al. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010, 62(2):177-188. [quiz: 189-90].
2. Safavi K.H., Muller S.A., Suman V.J., et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995, 70(7):628-633.
3. Wasserman D., Guzman-Sanchez D.A., Scott K., et al. Alopecia areata. Int J Dermatol 2007, 46(2):121-131.
4. Nanda A., Al-Fouzan A.S., Al-Hasawi F. Alopecia areata in children: a clinical profile. Pediatr Dermatol 2002, 19(6):482-485.
5. Price V.H. Alopecia areata: clinical aspects. J Invest Dermatol 1991, 96(5):68S.
6. Lu W., Shapiro J., Yu M., et al. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med 2006, 8(14):1-19.
7. Madani S., Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000, 42(4):549-566. [quiz: 567-70].
8. Tan C., Zhu W.Y., Min Z.S. A case of patchy alopecia areata sparing lesional greying hairs. Int J Dermatol 2008, 47(8):864-865.
9. Lew B.L., Shin M.K., Sim W.Y. Acute diffuse and total alopecia: a new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol 2009, 60(1):85-93.
10. Sato-Kawamura M., Aiba S., Tagami H. Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis. Dermatology 2002, 205(4):367-373.
11. Mane M., Nath A.K., Thappa D.M. Utility of dermoscopy in alopecia areata. Indian J Dermatol 2011, 56(4):407-411.
12. Ross E.K., Vincenzi C., Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006, 55(5):799-806.
13. Tosti A., Whiting D., Iorizzo M., et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol 2008, 59(1):64-67.
14. Gandhi V., Baruah M.C., Bhattacharaya S.N. Nail changes in alopecia areata: incidence and pattern. Indian J Dermatol Venereol Leprol 2003, 69(2):114-115.
15. Kasumagic-Halilovic E., Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 2009, 23(2):240-241.
16. Seyrafi H., Akhiani M., Abbasi H., et al. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol 2005, 5:11.
17. Kasumagic-Halilovic E. Thyroid autoimmunity in patients with alopecia areata. Acta Dermatovenerol Croat 2008, 16(3):123-125.
18. Hordinsky M., Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 2004, 9(1):73-78.
19. Goh C., Finkel M., Christos P.J., et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006, 20(9):1055-1060.
20. Rosenstein E.D., Warshauer B.L. Alopecia areata and autoimmunity. J Am Acad Dermatol 2010, 62(6):1065.
21. Ayuso V.K., Pott J.W., de Boer J.H. Intermediate uveitis and alopecia areata: is there a relationship? Report of 3 pediatric cases. Pediatrics 2011, 128(4):e1013-e1018.
22. Wang S.J., Shohat T., Vadheim C., et al. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA). Am J Med Genet 1994, 51(3):234-239.
23. Ruiz-Doblado S., Carrizosa A., Garcia-Hernandez M.J. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol 2003, 42(6):434-437.
24. Recupero S.M., Abdolrahimzadeh S., De Dominicis M., et al. Ocular alterations in alopecia areata. Eye (Lond) 1999, 13(Pt 5):643-646.
25. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002, 966:290-303.
26. Rodriguez T.A., Duvic M. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol 2008, 59(1):137-139.
27. Ikeda T. Produced alopecia areata based on the focal infection theory and mental motive theory. Dermatologica 1967, 134(1):1-11.
28. McElwee K.J., Silva K., Beamer W.G., et al. Melanocyte and gonad activity as potential severity modifying factors in C3H/HeJ mouse alopecia areata. Exp Dermatol 2001, 10(6):420-429.
29. McElwee K., Freyschmidt-Paul P., Ziegler A., et al. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol 2001, 11(1):11-16.
30. Petukhova L., Cabral R.M., Mackay-Wiggan J., et al. The genetics of alopecia areata: what's new and how will it help our patients?. Dermatol Ther 2011, 24(3):326-336.
31. Wang E., McElwee K.J. Etiopathogenesis of alopecia areata: why do our patients get it?. Dermatol Ther 2011, 24(3):337-347.
32. Tosti A., Bellavista S., Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 2006, 55(3):438-441.
33. Finner A.M. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther 2011, 24(3):348-354.
34. MacDonald Hull S.P., Wood M.L., Hutchinson P.E., et al. Guidelines for the management of alopecia areata. Br J Dermatol 2003, 149(4):692-699.
35. Todes-Taylor N., Turner R., Wood G.S., et al. T cell subpopulations in alopecia areata. J Am Acad Dermatol 1984, 11(2 Pt 1):216-223.
36. Dy L.C., Whiting D.A. Histopathology of alopecia areata, acute and chronic: why is it important to the clinician?. Dermatol Ther 2011, 24(3):369-374.
37. Whiting D.A. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003, 139(12):1555-1559.
38. Olsen E.A., Hordinsky M.K., Price V.H., et al. Alopecia areata investigational assessment guidelines-Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004, 51(3):440-447.
39. Kalkoff K.W., Macher E. Hautarzt 1958, 9(10):441-451. [in German].
40. Garg S., Messenger A.G. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009, 28(1):15-18.
41. Delamere F.M., Sladden M.M., Dobbins H.M., et al. Interventions for alopecia areata. Cochrane Database Syst Rev 2008, (2). CD004413.
42. Abell E., Munro D.D. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973, 88(1):55-59.
43. Porter D., Burton J.L. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971, 85(3):272-273.
44. Kubeyinje E.P. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994, 71(10):674-675.
45. Chang K.H., Rojhirunsakool S., Goldberg L.J. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009, 8(10):909-912.
46. Shapiro J., Price V.H. Hair regrowth. Therapeutic agents. Dermatol Clin 1998, 16(2):341-356.
47. Sohn K.C., Jang S., Choi D.K., et al. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun 2007, 356(3):810-815.
48. Pascher F., Kurtin S., Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970, 141(3):193-202.
49. Mancuso G., Balducci A., Casadio C., et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003, 42(7):572-575.
50. Tosti A., Piraccini B.M., Pazzaglia M., et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003, 49(1):96-98.
51. Tosti A., Iorizzo M., Botta G.L., et al. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006, 20(10):1243-1247.
52. Charuwichitratana S., Wattanakrai P., Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000, 136(10):1276-1277.
53. Bunker C.B., Dowd P.M. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 1987, 117(5):668-669.
54. Wester R.C., Maibach H.I., Guy R.H., et al. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984, 82(5):515-517.
55. Lachgar S., Charveron M., Gall Y., et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998, 138(3):407-411.
56. Mori O., Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990, 17(5):276-281.
57. Uno H., Cappas A., Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 1987, 16(3 Pt 2):657-668.
58. Buhl A.E., Waldon D.J., Conrad S.J., et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992, 98(3):315-319.
59. Messenger A.G., Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004, 150(2):186-194.
60. Price V.H. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987, 16(3 Pt 2):730-736.
61. Fiedler-Weiss V.C. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987, 16(3 Pt 2):745-748.
62. Fiedler-Weiss V.C., West D.P., Buys C.M., et al. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol 1986, 122(2):180-182.
63. Lucky A.W., Piacquadio D.J., Ditre C.M., et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004, 50(4):541-553.
64. Olsen E.A., Dunlap F.E., Funicella T., et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002, 47(3):377-385.
65. Olsen E.A., Whiting D., Bergfeld W., et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007, 57(5):767-774.
66. Schmoeckel C., Weissmann I., Plewig G., et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979, 115(10):1254-1255.
67. Fiedler-Weiss V.C., Buys C.M. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987, 123(11):1491-1493.
68. Tang L., Cao L., Sundberg J.P., et al. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 2004, 13(1):5-10.
69. Fiedler V.C., Wendrow A., Szpunar G.J., et al. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990, 126(6):756-759.
70. Sasmaz S., Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol 2005, 6(6):403-406.
71. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980, 267(1):109-114.
72. Herbst V., Zoller M., Kissling S., et al. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006, 16(5):537-542.
73. Happle R., Klein H.M., Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986, 278(3):214-218.
74. Wasylyszyn T., Kozlowski W., Zabielski S.L. Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone. Arch Dermatol Res 2007, 299(5-6):231-237.
75. Hoffmann R., Wenzel E., Huth A., et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994, 103(4):530-533.
76. Strobel R., Rohrborn G. Mutagenic and cell transforming activities of 1-chlor-2,4-dinitrobenzene (DNCB) and squaric-acid-dibutylester (SADBE). Arch Toxicol 1980, 45(4):307-314.
77. Summer K.H., Goggelmann W. 1-Chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella typhimurium. Mutat Res 1980, 77(1):91-93.
78. Wilkerson M.G., Henkin J., Wilkin J.K. Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol 1984, 11(5 Pt 1):802-807.
79. Wilkerson M.G., Henkin J., Wilkin J.K., et al. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 1985, 13(2 Pt 1):229-234.
80. Harries M.J., Sun J., Paus R., et al. Management of alopecia areata. BMJ 2010, 341:c3671.
81. Rokhsar C.K., Shupack J.L., Vafai J.J., et al. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998, 39(5 Pt 1):751-761.
82. Wiseman M.C., Shapiro J., MacDonald N., et al. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001, 137(8):1063-1068.
83. Orecchia G., Malagoli P., Santagostino L. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients. Pediatr Dermatol 1994, 11(1):65-68.
84. Orecchia G., Malagoli P. Topical immunotherapy in children with alopecia areata. J Invest Dermatol 1995, 104(Suppl 5):35S-36S.
85. Ganzetti G., Campanati A., Simonetti O., et al. Videocapillaroscopic pattern of alopecia areata before and after diphenylciclopropenone treatment. Int J Immunopathol Pharmacol 2011, 24(4):1087-1091.
86. van der Steen P.H., van Baar H.M., Happle R., et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991, 24(2 Pt 1):227-230.
87. Weise K., Kretzschmar L., John S.M., et al. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 1996, 192(2):129-133.
88. Galadari I., Rubaie S., Alkaabi J., et al. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 2003, 35(10):397-401.
89. Gordon P.M., Aldrige R.D., McVittie E., et al. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Br J Dermatol 1996, 134(5):869-871.
90. Ito T. Advances in the management of alopecia areata. J Dermatol 2012, 39(1):11-17.
91. Orecchia G., Perfetti L. Alopecia areata and topical sensitizers: allergic response is necessary but irritation is not. Br J Dermatol 1991, 124(5):509.
92. Dall'oglio F., Nasca M.R., Musumeci M.L., et al. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat 2005, 16(1):10-14.
93. Sotiriadis D., Patsatsi A., Lazaridou E., et al. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 2007, 32(1):48-51.
94. Francomano M., Seidenari S. Urticaria after topical immunotherapy with diphenylcyclopropenone. Contact Dermatitis 2002, 47(5):310-311.
95. Alam M., Gross E.A., Savin R.C. Severe urticarial reaction to diphenylcyclopropenone therapy for alopecia areata. J Am Acad Dermatol 1999, 40(1):110-112.
96. Tosti A., Guerra L., Bardazzi F. Contact urticaria during topical immunotherapy. Contact Dermatitis 1989, 21(3):196-197.
97. Perret C.M., Steijlen P.M., Zaun H., et al. Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990, 180(1):5-7.
98. Pan J.Y., Theng C., Lee J., et al. Vitiligo as an adverse reaction to topical diphencyprone. Ann Acad Med Singapore 2009, 38(3):276-277.
99. Henderson C.A., Ilchyshyn A. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Br J Dermatol 1995, 133(3):496-497.
100. Alkhalifah A. Topical and intralesional therapies for alopecia areata. Dermatol Ther 2011, 24(3):355-363.
101. Bearden W., Anderson R. Trichiasis associated with prostaglandin analog use. Ophthal Plast Reconstr Surg 2004, 20(4):320-322.
102. Tosti A., Pazzaglia M., Voudouris S., et al. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004, 51(Suppl 5):S149-S150.
103. Hart J., Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004, 137(4):756-757.
104. Herane M.I., Urbina F. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol 2004, 18(5):644-645.
105. Sasaki S., Hozumi Y., Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol 2005, 14(5):323-328.
106. Roseborough I., Lee H., Chwalek J., et al. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009, 60(4):705-706.
107. Ross E.K., Bolduc C., Lui H., et al. Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol 2005, 53(6):1095-1096.
108. Faghihi G., Andalib F., Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009, 19(6):586-587.
109. Coronel-Perez I.M., Rodriguez-Rey E.M., Camacho-Martinez F.M. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010, 24(4):481-485.
110. Vila T.O., Camacho Martinez F.M. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol 2010, 2(2):86-88.
111. Ochoa B.E., Sah D., Wang G., et al. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol 2009, 61(3):530-532.
112. Taylor C.R., Hawk J.L. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995, 133(6):914-918.
113. Healy E., Rogers S. PUVA treatment for alopecia areata-does it work? A retrospective review of 102 cases. Br J Dermatol 1993, 129(1):42-44.
114. Bayramgurler D., Demirsoy E.O., Akturk A.S., et al. Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol Photoimmunol Photomed 2011, 27(6):325-327.
115. Zakaria W., Passeron T., Ostovari N., et al. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol 2004, 51(5):837-838.
116. Raulin C., Gundogan C., Greve B., et al. J Dtsch Dermatol Ges 2005, 3(7):524-526. [in German].
117. Gundogan C., Greve B., Raulin C. Treatment of alopecia areata with the 308-nm xenon chloride excimer laser: case report of two successful treatments with the excimer laser. Lasers Surg Med 2004, 34(2):86-90.
118. Al-Mutairi N. 308-nm Excimer laser for the treatment of alopecia areata. Dermatol Surg 2007, 33(12):1483-1487.
119. Al-Mutairi N. 308-nm Excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol 2009, 26(5):547-550.
120. Talpur R., Vu J., Bassett R., et al. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009, 61(4):592.e1-592.e9.
121. Ehsani A.H., Toosi S., Seirafi H., et al. Capsaicin vs. clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol 2009, 23(12):1451-1453.
122. Yoo K.H., Kim M.N., Kim B.J., et al. Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol 2010, 49(7):845-847.
123. Wikramanayake T.C., Rodriguez R., Choudhary S., et al. Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata. Lasers Med Sci 2012, 27(2):431-436.
124. Kar B.R., Handa S., Dogra S., et al. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005, 52(2):287-290.
125. Ait Ourhroui M., Hassam B., Khoudri I. Ann Dermatol Venereol 2010, 137(8-9):514-518.
126. Olsen E.A., Carson S.C., Turney E.A. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992, 128(11):1467-1473.
127. Price V.H. Treatment of hair loss. N Engl J Med 1999, 341(13):964-973.
128. Sharma V.K., Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol 1999, 26(9):562-565.
129. Friedli A., Labarthe M.P., Engelhardt E., et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998, 39(4 Pt 1):597-602.
130. Kurosawa M., Nakagawa S., Mizuashi M., et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006, 212(4):361-365.
131. Alkhalifah A., Alsantali A., Wang E., et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010, 62(2):191-202. [quiz: 203-4].
132. Lester R.S., Knowles S.R., Shear N.H. The risks of systemic corticosteroid use. Dermatol Clin 1998, 16(2):277-288.
133. Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol 2011, 4:107-115.
134. Gupta A.K., Ellis C.N., Cooper K.D., et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 1990, 22(2 Pt 1):242-250.
135. Kim B.J., Min S.U., Park K.Y., et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat 2008, 19(4):216-220.
136. Shapiro J., Lui H., Tron V., et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997, 36(1):114-117.
137. Shaheedi-Dadras M., Karami A., Mollaei F., et al. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med 2008, 11(1):90-93.
138. Cerottini J.P., Panizzon R.G., de Viragh P.A. Multifocal alopecia areata during systemic cyclosporine A therapy. Dermatology 1999, 198(4):415-417.
139. Dyall-Smith D. Alopecia areata in a renal transplant recipient on cyclosporin. Australas J Dermatol 1996, 37(4):226-227.
140. Phillips M.A., Graves J.E., Nunley J.R. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol 2005, 53(5 Suppl 1):S252-S255.
141. Davies M.G., Bowers P.W. Alopecia areata arising in patients receiving cyclosporin immunosuppression. Br J Dermatol 1995, 132(5):835-836.
142. Lee D., Hong S.K., Park S.W., et al. Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids. Exp Dermatol 2010, 19(2):145-147.
143. Otberg N. Systemic treatment for alopecia areata. Dermatol Ther 2011, 24(3):320-325.
144. Gilhar A., Pillar T., Etzioni A. Topical cyclosporin A in alopecia areata. Acta Derm Venereol 1989, 69(3):252-253.
145. Mauduit G., Lenvers P., Barthelemy H., et al. Ann Dermatol Venereol 1987, 114(4):507-510. [in French].
146. Verma D.D., Verma S., McElwee K.J., et al. Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur J Dermatol 2004, 14(5):332-338.
147. Ranganath V.K., Furst D.E. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007, 33(1):197-217.
148. Ellis C.N., Brown M.F., Voorhees J.J. Sulfasalazine for alopecia areata. J Am Acad Dermatol 2002, 46(4):541-544.
149. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol 2008, 74(6):611-613.
150. Rashidi T., Mahd A.A. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol 2008, 47(8):850-852.
151. Chartaux E., Joly P. Ann Dermatol Venereol 2010, 137(8-9):507-513. [in French].
152. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006, 55(4):632-636.
153. Royer M., Bodemer C., Vabres P., et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol 2011, 165(2):407-410.
154. Farshi S., Mansouri P., Safar F., et al. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol 2010, 49(10):1188-1193.
155. Cipriani R., Perini G.I., Rampinelli S. Paroxetine in alopecia areata. Int J Dermatol 2001, 40(9):600-601.
156. Willemsen R., Vanderlinden J., Deconinck A., et al. Hypnotherapeutic management of alopecia areata. J Am Acad Dermatol 2006, 55(2):233-237.
157. Price V.H., Willey A., Chen B.K. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005, 52(1):138-139.
158. Thiers B.H. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000, 136(1):124.
159. Rigopoulos D., Gregoriou S., Korfitis C., et al. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol 2007, 32(4):456-457.
160. Feldmann K.A., Kunte C., Wollenberg A., et al. Is topical tacrolimus effective in alopecia areata universalis?. Br J Dermatol 2002, 147(5):1031-1032.
161. Park S.W., Kim J.W., Wang H.Y. Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002, 82(5):387-388.
162. Koc E., Tunca M., Akar A., et al. Lack of efficacy of topical imiquimod in the treatment of patchy alopecia areata. Int J Dermatol 2008, 47(10):1088-1089.
163. D'Ovidio R., Claudatus J., Di Prima T. Ineffectiveness of imiquimod therapy for alopecia totalis/universalis. J Eur Acad Dermatol Venereol 2002, 16(4):416-417.
164. Bissonnette R., Shapiro J., Zeng H., et al. Topical photodynamic therapy with 5-aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata. Br J Dermatol 2000, 143(5):1032-1035.
165. Fernandez-Guarino M., Harto A., Garcia-Morales I., et al. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol 2008, 33(5):585-587.
166. Garcia Bartels N., Lee H.H., Worm M., et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006, 142(12):1654-1655.
167. Kirshen C., Kanigsberg N. Alopecia areata following adalimumab. J Cutan Med Surg 2009, 13(1):48-50.
168. Chaves Y., Duarte G., Ben-Said B., et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 2008, 217(4):380.
169. Pelivani N., Hassan A.S., Braathen L.R., et al. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008, 216(4):320-323.
170. Ettefagh L., Nedorost S., Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004, 140(8):1012.
171. Fabre C., Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008, 216(2):185-186.
172. Posten W., Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005, 141(6):759-760.
173. Abramovits W., Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed 2006, 5(4):177-181.
174. Pan Y., Rao N.A. Alopecia areata during etanercept therapy. Ocul Immunol Inflamm 2009, 17(2):127-129.